Key considerations and best practices for viral vaccine process development, scale-up and implementation at manufacturing scale including single use technologies

M9

Course Goals 

Process development and scale-up of viral vaccines.

Timeline 

Application Deadline:
June 2021

Course Dates:
Q3 2021 (2 days)

Organiser

Vaccine Formulation Insitute (VFI) in collaboration with Merck/M Lab, Molsheim, France

​Participant Nr.: 10

Contact

Course content

Using a combination of theory and hands-on instruction, participants will learn the following:

- Key best practices and methods for vaccine process development from upstream to downstream focusing on a viral vaccine platform.

Best practices of cell culturing in single use bioreactors for both adherent and suspension cells;

Optimization of filtration and purification technologies;

Adjuvant filtration;

- How to integrate vaccine processes in a single use environment;

Learning Outcomes

Understand challenges and integrate key considerations for optimal viral vaccine process development and transition to manufacturing Learn how to implement a single use technology based process for viral vaccines.

Who should apply

This course is designed for R&D scientists and engineers who are or will be responsible for developing and implementing production scale viral vaccine processes.

Minimal requirements

Prior experience with laboratory scale vaccine and/or biologics process development.

Accommodation

Accommodation will be provided. Travel costs are not included.

Comments

* Due to COVID19 related delays call and training modules' schedule may be subject to change.
Be the first to know about the upcoming application calls, follow European Vaccine Initiative on Twitter and LinkedIn or subscribe to TRANSVAC Newsletter.

Weblink

Back to Training Modules

Be the first to know about the upcoming application calls, follow European Vaccine Initiative on:

  • LinkedIn Social Icon
  • Twitter Social Icon

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 730964.

Subscribe to TRANSVAC´s Mailing list

© 2021 European Vaccine Initiative. Designed by European Vaccine Initiative